NCT01743768View on ClinicalTrials.gov

Safety, Efficacy, PK, and PD Characteristics of Orally Inhaled SB010 in Male Patients With Mild Asthma (Multiple Dose)

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

December 31, 2013

Conditions
Asthma
Interventions
DRUG

SB010

Treatment group (n=19), receiving the active drug substance.

DRUG

Placebo

Treatment group (n=19), receiving placebo.

Trial Locations (7)

D-10117

Charité Research Organisation GmbH, Berlin

D-60596

Clinical Research Centre RespiratoryMedicine (IKF), Frankfurt

D-82131

Inamed GmbH, Gauting

D-22927

Pulmonary Research Institute (PRI), Großhansdorf

D-30625

Clinical Airway Research Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hanover

D-55131

Johannes Gutenberg University Medical Clinic III for Hematology, Oncology and Pneumology, Mainz

D-65187

insaf - Respiratory Research Institute GmbH, Wiesbaden

All Listed Sponsors
lead

Sterna Biologicals GmbH & Co. KG

INDUSTRY

NCT01743768 - Safety, Efficacy, PK, and PD Characteristics of Orally Inhaled SB010 in Male Patients With Mild Asthma (Multiple Dose) | Biotech Hunter | Biotech Hunter